文献速递肾小球疾病

膜性肾病无创诊断策略:NEPTUNE队列研究

Noninvasive Diagnostic Strategies for Membranous Nephropathy in the Nephrotic Syndrome Study Network.
PubMed 文献 · Clin J Am Soc Nephrol · 2025-02-28

基于Nephrotic Syndrome Study Network队列,在肾活检前或活检时采集325例患者血清,评估PLA2R抗体ELISA、间接免疫荧光(IIF)及遗传风险评分(GRS)联合诊断膜性肾病(MN)的性能。ELISA≥2 RU/ml且IIF阳性为最优策略,灵敏度0.60、特异度1.00、阴性预测值0.92、阳性预测值1.00;仅对ELISA 2–20 RU/ml的临界值用IIF确认可获得相似灵敏度且特异度>0.99;加用GRS未改善诊断性能。

要点

  • ELISA≥2 RU/ml联合IIF阳性诊断PLA2R相关MN特异度达1.00、阳性预测值1.00。
  • 对ELISA 2–20 RU/ml的临界值仅用IIF确认,灵敏度相似且特异度>0.99。
  • 在多民族队列中,加用遗传风险评分未改善诊断性能。

核心结论

  • 联合PLA2R-Ab ELISA与IIF可在肾活检前或活检后不久实现MN的无创诊断,包括亚肾病范围蛋白尿患者。

研究设计与样本

  • 采用Nephrotic Syndrome Study Network参与者肾活检当日或之前的血清样本,共325例;另143例为活检后6个月内且未用免疫抑制前的样本。
  • 以肾活检确诊MN为参照,分析PLA2R-Ab ELISA、IIF及GRS不同组合和阈值的诊断性能。

主要发现

  • 325例中26%(n=85)为活检确诊MN。
  • ELISA≥2 RU/ml且IIF阳性:灵敏度0.60、特异度1.00、阴性预测值0.92、阳性预测值1.00。
  • 仅对ELISA 2–20 RU/ml的临界值用IIF确认:灵敏度相似,特异度>0.99。
  • 在多民族样本中,加用GRS未观察到诊断性能改善。

关键数值与推荐

  • 推荐联合ELISA≥2 RU/ml与IIF阳性作为无创诊断PLA2R相关MN的最优策略。
  • 对ELISA 2–20 RU/ml的临界值可用IIF确认,以维持高特异度。

临床怎么用

  • 对蛋白尿患者可联合PLA2R-Ab ELISA与IIF无创诊断PLA2R相关MN,减少肾活检需求。
  • ELISA临界值(2–20 RU/ml)时应加做IIF确认以提高特异度。

局限性

  • 需在多民族人群中进一步研究遗传数据能否增强该诊断策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: Antiphospholipase A2 receptor antibody seropositivity by ELISA ≥2 and positive indirect immunofluorescence was optimal. Noninvasive diagnosis of phospholipase A2 receptor–associated membranous nephropathy among patients with proteinuria is feasible using both assays. BACKGROUND: Clinical practice guidelines recommend that a kidney biopsy is no longer required to confirm a diagnosis of membranous nephropathy (MN) in patients with nephrotic syndrome and a positive test for antiphospholipase A2 receptor antibodies (PLA2R-Ab). However, the optimal diagnostic strategy for using the PLA2R-Ab ELISA, PLA2R-Ab indirect immunofluorescence (IIF) test, and genetic risk score (GRS) for diagnosing MN, including the tests' optimal thresholds for positivity among incident patients with proteinuria, is still unknown. METHODS: We used serum samples at or before the first clinically indicated kidney biopsy from participants in the Nephrotic Syndrome Study Network to analyze test performance characteristics using different combinations and cutoffs of the PLA2R-Ab ELISA, IIF, and GRS for diagnosing MN. Secondary analyses included serum samples within 6 months after biopsy but before any immunosuppression use. RESULTS: There were 325 study participants with serum samples available on or before the day of kidney biopsy and an additional 143 study participants with samples within 6 months after biopsy but before any immunosuppression use. Of these participants, 26% (n=85) had biopsy-confirmed MN. The combination of ELISA ≥2 RU/ml and positive IIF was the optimal approach, with sensitivity of 0.60, specificity of 1.00, negative predictive value of 0.92, and positive predictive value of 1.00. Using IIF to confirm only borderline ELISA titers between 2 and 20 RU/ml resulted in similar sensitivity but specificity of >0.99. In our multiethnic study sample, we did not find improved diagnostic performance with the addition of GRSs. CONCLUSIONS: In the Nephrotic Syndrome Study Network cohort, combined PLA2R-Ab testing with ELISA and IIF provided optimal test characteristics in making a noninvasive diagnosis of MN before or soon after kidney biopsy, including in patients with subnephrotic proteinuria. Further studies in multiethnic populations are needed to assess whether genetic data can augment this approach.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Zee J, Hogan JJ, Abdullah A, et al. Noninvasive Diagnostic Strategies for Membranous Nephropathy in the Nephrotic Syndrome Study Network. Clin J Am Soc Nephrol. 2025. PMID: 40019793. doi:10.2215/CJN.0000000671

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。